A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer

A. L. Cohn, J. Tabernero, J. Maurel, E. Nowara, J. Sastre, B. Y.S. Chuah, M. V. Kopp, D. D. Sakaeva, E. P. Mitchell, S. Dubey, S. Suzuki, Y. J. Hei, F. Galimi, I. McCaffery, Y. Pan, R. Loberg, S. Cottrell, S. P. Choo

Research output: Contribution to journalArticleResearchpeer-review

63 Citations (Scopus)

Abstract

Background: Targeted agents presently available for mutant KRAS metastatic colorectal cancer (mCRC) are bevacizumab and aflibercept. We evaluated the efficacy and safety of conatumumab (an agonistic monoclonal antibody against human death receptor 5) and ganitumab (a monoclonal antibody against the type 1 insulin-like growth factor receptor) combined with standard FOLFIRI chemotherapy as a second-line treatment in patients with mutant KRAS mCRC. Patients and methods: Patients with mutant KRAS metastatic adenocarcinoma of the colon or rectum refractory to fluoropyrimidine- and oxaliplatin-based chemotherapy were randomized 1: 1: 1 to receive intravenous FOLFIRI plus conatumumab 10 mg/kg (Arm A), ganitumab 12 mg/kg (Arm B), or placebo (Arm C) Q2W. The primary end point was progression-free survival (PFS). Results: In total, 155 patients were randomized. Median PFS in Arms A, B, and C was 6.5 months (HR, 0.69; P = 0.147), 4.5 months (HR, 1.01; P = 0.998), and 4.6 months, respectively; median overall survival was 12.3 months (HR, 0.89; P = 0.650), 12.4 months (HR, 1.27; P = 0.357), and 12.0 months; and objective response rate was 14%, 8%, and 2%. The most common grade ≥3 adverse events in Arms A/B/C included neutropenia (30%/25%/18%) and diarrhea (18%/2%/10%). Conclusions: Conatumumab, but not ganitumab, plus FOLFIRI was associated with a trend toward improved PFS. Both combinations had acceptable toxicity. ©The Author 2013.Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.
Original languageEnglish
Article numbermdt057
Pages (from-to)1777-1785
JournalAnnals of Oncology
Volume24
Issue number7
DOIs
Publication statusPublished - 1 Jul 2013

Keywords

  • Conatumumab
  • FOLFIRI
  • Ganitumab
  • KRAS
  • Metastatic colorectal cancer

Fingerprint Dive into the research topics of 'A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer'. Together they form a unique fingerprint.

Cite this